Study on the efficacy and safety of oxaliplatin fumarate injection combined with low-dose sufentanil for postoperative analgesia in kidney transplant patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500103170

Enrollment

Unknown

Registered

2025-05-26

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure

Interventions

Group A:Oxalidine PCA 0.35mg

Group A:sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) 18 <= Age<65 years old, Body Mass Index 18-30kg/m^2, ASA II-IV grade; (2) No severe central nervous system, lung, liver, brain dysfunction, etc; (3) Cognitive function is normal, with the ability to autonomously describe pain levels.

Exclusion criteria

Exclusion criteria: (1) History of alcohol abuse, use of antipsychotic drugs, and dependence on narcotic drugs; (2) Individuals with abnormal function of important organs.

Design outcomes

Primary

Measure	Time frame
Pain score;Renal function;	—

Countries

China

Contacts

Public Contactma xiangfei

The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi

17031861@qq.com+86 137 0788 8837

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026